Chinese scientist says Beijing did share COVID-19 data with investigators

By Gabriel Crossley

BEIJING (Reuters) -A top Chinese medical expert said on Wednesday there was no factual basis to accusations that China did not share data with international researchers appointed by the World Health Organization to look into the origins of COVID-19.

Following the publication of the joint study into the origins of COVID-19 by China and the WHO on Tuesday, WHO Director General Tedros Adhanom Ghebreyesus said China had withheld data from the international investigators.

But Liang Wannian, who was co-leader of the joint study, told reporters that researchers from both sides had access to the same data throughout the investigation and that the assertions about lack of access were not accurate.

“Of course, according to Chinese law, some data cannot be taken away or photographed, but when we were analyzing it together in Wuhan, everyone could see the database, the materials – it was all done together,” he said.

Responding to allegations that the expert panel did not have access to complete datasets and samples, Liang said no scientist ever had perfect information.

He also rejected complaints that the publication of the report had been repeatedly delayed, noting that “every sentence, every conclusion, every piece of data” needed to be verified by both sides before it could be released.

“Throughout we always upheld the principle of ‘quality comes first,'” said Liang, who is the head of a committee of experts on COVID-19 set up by China’s National Health Commission.

The joint study concluded that the most likely origin of COVID-19 was in animals, and probably passed through an intermediary species before it entered humans.

It also said more efforts were needed to see if COVID-19 could be traced back to wildlife farms in both China and southeast Asia.

Liang said China would continue to try to trace the origins of COVID-19, but the Chinese part of the joint research had been completed, and attention should now turn to other countries.

Tracing the origins of COVID-19 couldn’t be achieved overnight, he said.

“There are lots of diseases that have circulated for a long time and we still haven’t found their origins,” he said. “It still needs a lot of time.”

(Reporting by Gabriel Crossley; Writing by David Stanway; Editing by William Maclean and Andrew Heavens)

COVID curbs having less impact at keeping Parisians at home: data

By Caroline Pailliez and Leigh Thomas

PARIS (Reuters) – The French government’s anti-COVID-19 measures are having half the impact in encouraging Parisians to stay at home as the restrictions in France’s first lockdown, data shows, underscoring why epidemiologists say the curbs are too weak to stop a third wave of infection over-running hospitals.

Google data shows residents in the capital, the epicenter of a fast-spreading third wave of infections, are spending just 20% more time at home than during pre-crisis times, compared with 40% during the strict three-month lockdown last spring.

The data reflects the tough reality confronting President Emmanuel Macron, who, according to one source close to the government, will have to decide on Wednesday whether to resort once again to a draconian lockdown that risks upending economic activity.

“We have to limit the spread of the virus and we won’t do that with these half-measures,” said Gilles Pialoux, head of infectious diseases at the Tenon hospital in Paris.

The government closed some non-essential stores and limited how far people could travel, adding to a nationwide nightly curfew, in the hardest hit regions on March 20.

While Apple Maps data shows a slight fall in journeys made by car, public transport or on foot, people remain on the move more than during either the spring or autumn lockdowns.

To be sure, part of this is by design. Macron wants to keep the euro zone’s second largest economy open and allow citizens to spend time outdoors. But it also underlines the extent to which government appeals for people to voluntarily restrict their movements are falling on deaf ears.

Intensive care wards are reaching breaking point. In Paris, there are now more COVID-19 patients in ICUs than at the peak of the second wave in November, and critical care wards are operating at 140% of normal bed capacity.

‘CRUSH THE VIRUS’

Macron will convene his COVID-19 war room on Wednesday at a time the surge in coronavirus infections is dragging the death count towards the 100,000 threshold.

The president has this year repeatedly sought to avoid another lockdown, counting on COVID-19 vaccines to reduce the numbers falling gravely ill.

But the vaccine rollout is only now hitting its stride, with about 12% of the population inoculated after three months. Meanwhile, the science shows a vaccinated person can still transmit the virus and it will not be until late summer before all adults have been offered a shot.

“You absolutely first have to crush the virus’ prevalence,” said Philippe Amouyel, head of epidemiology at Lille Hospital, “then afterwards comes the vaccine.”

A full-blown lockdown would entail closing schools and prohibiting people from leaving their home other than for essential reasons such as buying groceries, seeking medical help and exercise.

No decision has yet been taken, a government source said.

If a strict lockdown was imposed across France, the number of intensive care patients in the Paris region would peak at about 3,470 on April 22, according to Paris hospital trust forecasts that Reuters has seen.

If the decision was delayed by one week, that number would rise to 4,470 on April 29, the model predicts. During the first wave, ICU admissions peaked at 2,668.

Police unions told Reuters a full lockdown would be easier to enforce than the unwieldy array of rules now in place.

Last weekend crowds thronged the banks of the Seine in Paris. Police urged picnickers to sit apart but there was little evidence of checks being made on whether people had travelled further than the permitted 10 km (6.2 miles) to be there.

“We see that people now have a little less respect for the rules,” said Denis Jacob of the CFDT union’s police branch. “But it’s very difficult to enforce this set of rules.”

(Reporting by Caroline Pailliez and Leigh Thomas; Additional reporting by Elizabeth Pineau; Writing by Richard Lough; Editing by Jonathan Oatis)

Immune response may be linked to AstraZeneca vaccine clot issue; death risk rising among young adults in Brazil

By Nancy Lapid

(Reuters) -The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Immune response may explain rare clots after AstraZeneca vaccine

Researchers may have found an explanation for the rare but serious blood clots reported among some people who received AstraZeneca’s COVID-19 vaccine. They believe the phenomenon is similar to one that rarely occurs with a blood thinning drug called heparin, called heparin-induced thrombocytopenia (HIT). In HIT, the drug triggers the immune system to produce antibodies that activate platelets, which cause blood to clot. Drugs other than heparin can cause clotting disorders that strongly resemble HIT, and researchers suspect that in rare cases, the AstraZeneca vaccine may be another such trigger. Four previously healthy individuals who got the AstraZeneca shot and developed life-threatening clots had the same kind of antibodies that activate platelets and initiate clotting in HIT, the researchers reported on Monday in a paper posted on Research Square ahead of peer review. Twenty individuals who received the vaccine but did not develop clots did not have these antibodies. An editorial comment posted with the study noted that drug-induced thrombocytopenia is treatable if identified promptly. Millions of people have received the vaccine without issues and European regulators and the World Health Organization say the benefits of the AstraZeneca shot outweigh its risks.

COVID-19 death risk rising for young adults in Brazil

Southern Brazil is seeing a sudden rise in COVID-19 deaths among young and middle-aged adults after the identification there of a concerning virus variant known as P.1, researchers said. They analyzed data from Parana – the largest state in southern Brazil – on 553,518 cases diagnosed from September 2020 through March 17, 2021. In all age groups, the proportion of patients who died either held steady or declined between September and January. Starting in February, however, fatality rates rose for almost all groups over age 20, according to a report posted on Friday on medRxiv ahead of peer review. From January to February, these rates tripled among patients aged 20 to 29, from 0.04% to 0.13%, and doubled among those aged 30 to 39, 40 to 49, and 50 to 59. “Individuals between 20 and 29 years of age whose diagnosis was made in February 2021 had an over 3-fold higher risk of death compared to those diagnosed in January 2021,” the researchers said. “Taken together, these preliminary findings suggest significant increases in case fatality rates in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil, and this should raise public health alarms.”

Pfizer, Moderna vaccines limit asymptomatic infections

Vaccines from Pfizer Inc and partner BioNTech SE and from Moderna Inc dramatically reduced the risk of infection by the new coronavirus within weeks after the first of two shots, according to data from a study of nearly 4,000 U.S. healthcare personnel and first responders in six states. Previous trials by the companies evaluated the vaccines’ efficacy in preventing illness from COVID-19, but would have missed infections that did not cause symptoms. In the new study, conducted from mid-December to mid-March, nearly 75% of participants had received at least one dose of vaccine, and everyone had weekly coronavirus testing for 13 consecutive weeks in order to pick up asymptomatic infections. According to a report published on Monday by the U.S. Centers for Disease Control and Prevention (CDC), the risk of infection fell by 80% two weeks or more after the first of two shots and by 90% by two weeks after the second shot. “The authorized mRNA COVID-19 vaccines provided early, substantial real-world protection against infection for our nation’s healthcare personnel, first responders, and other frontline essential workers,” CDC Director Rochelle Walensky said in a statement.

Pandemic has cut parents’ access to hospitalized children

Pediatricians have long endorsed the idea that babies and children in hospitals should not be separated from their families – a practice that in many facilities was restricted or discontinued to limit COVID-19 infections, according to new research. From mid-May through early July, researchers collected survey responses from 96 pediatric care units in 22 countries in Europe, Asia, and North America. The results – mostly from intensive care units for newborns – showed that before the pandemic, 87% of units welcomed families and 92% encouraged skin-to-skin care, according to a report published in Journal of Perinatology. After the onset of the pandemic, more than 83% of the hospital units restricted family presence, with additional restrictions placed on parental participation in their infant’s care, said study coauthor Ita Litmanovitz of Meir Medical Center in Kfar Saba, Israel. Hospitals’ decisions to limit family access did not depend on their previous rules, the availability of single-family rooms, or the virus infection rate in the hospital’s geographical area. “Restrictions during the pandemic increased separation between the infant and family,” the researchers found. These restrictions, Litmanovitz added, “go against psychological and neuroscientific evidence in support of unrestricted parental presence and ability to care for their hospitalized infants.”

(Reporting by Nancy Lapid; Editing by Bill Berkrot)

Data withheld from WHO team probing COVID-19 origins in China: Tedros

By Stephanie Nebehay and John Miller

GENEVA/ZURICH (Reuters) – Data was withheld from World Health Organization investigators who travelled to China to research the origins of the coronavirus epidemic, WHO Director-General Tedros Adhanom Ghebreyesus said on Tuesday.

The United States, the European Union and other Western countries immediately called for China to give “full access” to independent experts to all data about the original outbreak in late 2019.

In its final report, written jointly with Chinese scientists, a WHO-led team that spent four weeks in and around Wuhan in January and February said the virus had probably been transmitted from bats to humans through another animal, and that a lab leak was “extremely unlikely” as a cause.

One of the team’s investigators has already said China refused to give raw data on early COVID-19 cases to the WHO-led team, potentially complicating efforts to understand how the global pandemic began.

“In my discussions with the team, they expressed the difficulties they encountered in accessing raw data,” Tedros said. “I expect future collaborative studies to include more timely and comprehensive data sharing.”

The inability of the WHO mission to conclude yet where or how the virus began spreading in people means that tensions will continue over how the pandemic started – and whether China has helped efforts to find out or, as the United States has alleged, hindered them.

“The international expert study on the source of the SARS-CoV-2 virus was significantly delayed and lacked access to complete, original data and samples,” Australia, Canada, the Czech Republic, Denmark, Estonia, Israel, Japan, Latvia, Lithuania, Norway, Korea, Slovenia, Britain, the United States and the European Union said in a joint statement.

“NOT EXTENSIVE ENOUGH”

Although the team concluded that a leak from a Wuhan laboratory was the least likely hypothesis for the virus that causes COVID-19, Tedros said the issue required further investigation, potentially with more missions to China.

“I do not believe that this assessment was extensive enough,” he told member states in remarks released by the WHO. “Further data and studies will be needed to reach more robust conclusions.”

The WHO team’s leader, Peter Ben Embarek, told a press briefing it was “perfectly possible” the virus had been circulating in November or October 2019 around Wuhan, and so potentially spreading abroad earlier than documented so far.

“We got access to quite a lot of data in many different areas, but of course there were areas where we had difficulties getting down to the raw data and there are many good reasons for that,” he said, citing privacy laws and other restrictions.

Second phase studies were required, Ben Embarek added.

He said the team had felt political pressure, including from outside China, but that he had never been pressed to remove anything from its final report.

Dominic Dwyer, an Australian expert on the mission, said he was satisfied there was “no obvious evidence” of a problem at the Wuhan Institute of Virology.

The European Union called the study “an important first step” but renewed criticisms that the origin study had begun too late, that experts had been kept out of China for too long, and that access to data and early samples had fallen short.

In a statement, Walter Stevens, EU ambassador to the United Nations in Geneva, called for further study with “timely access to relevant locations and to all relevant human, animal and environmental data available”.

(Reporting by Stephanie Nebehay, John Miller and Emma Farge; Editing by Mark Heinrich and Kevin Liffey)

Leaders of 23 countries back pandemic treaty idea for future emergencies

GENEVA/BRUSSELS (Reuters) – Leaders of 23 countries and the World Health Organization on Tuesday backed an idea to create an international treaty that would help deal with future health emergencies like the coronavirus pandemic by tightening rules on sharing information.

The idea of such a treaty, also aimed at ensuring universal and equitable access to vaccines, medicines and diagnostics for pandemics, was floated by the chairman of European Union leaders, Charles Michel, at a summit of the Group of 20 major economic powers last November.

WHO Director-General Tedros Adhanom Ghebreyesus has endorsed the proposal, but formal negotiations have not begun, diplomats say.

Tedros told a news conference on Tuesday that a treaty would tackle gaps exposed by the COVID-19 pandemic. A draft resolution on negotiations could be presented to the WHO’s 194 member states at their annual ministerial meeting in May, he said.

The WHO has been criticized for its handling of the COVID-19 pandemic and was accused by the administration of U.S. president Donald Trump of helping China shield the extent of its outbreak, which the agency denies.

A joint WHO-China study on the virus’s origins, seen by Reuters on Monday, said it had probably been transmitted from bats to humans through another animal, and that a lab leak was “extremely unlikely” as a cause. But the study left many questions unanswered and called for further research.

On Tuesday, the treaty proposal got the formal backing of the leaders of Fiji, Portugal, Romania, Britain, Rwanda, Kenya, France, Germany, Greece, Korea, Chile, Costa Rica, Albania, South Africa, Trinidad and Tobago, the Netherlands, Tunisia, Senegal, Spain, Norway, Serbia, Indonesia, Ukraine and the WHO itself.

“There will be other pandemics and other major health emergencies. No single government or multilateral agency can address this threat alone,” the leaders wrote in a joint opinion piece in major newspapers.

“We believe that nations should work together towards a new international treaty for pandemic preparedness and response.”

The leaders of China and the United States did not sign the letter, but Tedros said both powers had reacted positively to the proposal, and all states would be represented in talks.

The treaty would complement the WHO’s International Health Regulations, in force since 2005, through cooperation in controlling supply chains, sharing virus samples and research and development, WHO assistant director Jaouad Mahjour said.

(Reporting by Jan Strupczewski and Philip Blenkinsop in Brussels and Stephanie Nebehay in Geneva; Editing by Kevin Liffey)

Spain’s rising COVID-19 rate gathers pace

MADRID (Reuters) – Spain’s coronavirus infection rate rose by more than 10 since Friday, with 15,500 cases added to the tally, Health Ministry data showed on Monday, as a gradual uptick in contagion from mid-March lows gathered pace.

The rate, which is measured over the preceding 14 days, rose to 149 cases per 100,000 people from 138 cases on Friday, the data showed.

It had been inching higher since dropping below 130 cases per 100,000 people in mid-March and remains well below the peak of nearly 900 cases recorded in late January.

Monday’s infection numbers brought the total since the start of the pandemic to 3.27 million cases. The death toll climbed by 189 since Friday to 75,199.

“At a national level we are in a phase of expansion” of new cases, Health Emergency Chief Fernando Simon told a news conference, adding that the trend was likely to continue in the coming days.

Though bars and restaurants remain open in much of the country, Spain has banned travel between different regions and limited social events to four people during Holy Week to prevent Easter celebrations triggering a fresh resurgence in contagion.

“If we manage to follow the Easter restrictions, we may not be talking about a fourth wave,” Simon said.

(Reporting by Nathan Allen; editing by Jonathan Oatis)

Philippines sees 10,000 new COVID-19 cases as tight curbs return to capital

By Neil Jerome Morales

MANILA (Reuters) – The Philippines passed the 10,000 mark for new daily coronavirus infections for the first time on Monday and put its capital region back on one of its toughest levels of lockdown, to try to tackle a spike in cases that is testing its healthcare capacity.

Manila and surrounding provinces were put back under enhanced community quarantine (ECQ), the highest tier in its containment protocols, for the first time since May 2020 to try to quell the surge in cases, despite inroads late last year towards controlling its epidemic.

The country recorded 10,016 new infections on Monday, bringing the overall tally to 731,894, with deaths at 13,186, one of the highest caseloads in Asia.

Health experts say the surge in infections underscores the need to expedite a national vaccination drive, with only 656,331 healthcare workers so far given their first of two shots. The government aims to inoculate 70 million people this year.

It has also struggled to secure vaccine supplies, with an inventory of 2.525 million doses, mostly of Sinovac Biotech’s vaccine, one million of which arrived on Monday.

Philippines President Rodrigo Duterte on Monday allowed the private sector to import vaccines to boost supply and help reopen the economy.

“Whatever the cost, whatever the volume they want to bring in, it’s fine with me,” Duterte said in a national address.

Prior to Duterte’s approval, businesses go through the government for supply deals. Previously, half of the purchased doses were required to be given to the government.

Health authorities blame the spike on poor public compliance with prevention measures and the presence of new and more transmissible coronavirus variants in the capital region, which accounts for about a third of economic activity.

“This surge is really challenging while ECQ is painful, particularly for the economic sector,” said Benjamin Co, an infectious disease expert with three Manila hospitals.

The Philippines was the first country in Asia to go under a nationwide lockdown and broad restrictions and movement curbs saw its economy slump 9.5% last year, its worst economic contraction on record.

Hospitals’ intensive care and isolation bed capacity in the capital region have reached critical levels or above 70% usage, government data showed.

“I can give you beds, I can give you rooms. The problem is I cannot give you additional manpower capacity, like nurses and doctors to take care of you,” Co added.

(Reporting by Neil Jerome Morales; Editing by Ed Davies and Marguerita Choy)

More under-30 Americans report anxiety, depression during pandemic – CDC

By Vishwadha Chander

(Reuters) – More young adults in the United States reported feeling anxious or depressed during the past six months of the COVID-19 pandemic, and fewer people reported getting the help they needed, according to a U.S. government study released on Friday.

The percentage of adults under age 30 with recent symptoms of an anxiety or a depressive disorder rose significantly about five months after the U.S. imposed COVID-19 related lockdowns, and reported rising deaths from the fast-spreading virus.

Between August 2020 and February 2021, this number went up to 41.5% from 36.4%, as did the percentage of such people reporting that they needed, but did not receive, mental health counseling.

The study suggests that the rise in anxiety or depressive disorder symptoms reported correspond with the weekly number of reported COVID-19 cases.

The findings are based on a Household Pulse Survey conducted by the U.S. Centers for Disease Control and Prevention (CDC) and the Census Bureau to monitor changes in mental health status and access to care during the pandemic.

“Trends in mental health can be used to evaluate the impact of strategies addressing adult mental health status and care during the pandemic, “the authors of the study wrote in the CDC’s Morbidity and Mortality Weekly Report released on Friday.

The study also found those with less than a high school education were more at risk, though it did not provide an explanation for it.

Even with more vaccines gaining authorization beginning late 2020, the effects of the pandemic on mental health continued into 2021.

During Jan. 20, 2021 through Feb. 1, 2021, about two in five adults aged over 18 years experienced recent symptoms of an anxiety or a depressive disorder, the survey found.

Demand for mental health and meditation apps, and investments in tech startups building these apps have also risen during this period.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Caroline Humer and Shailesh Kuber)

Dying in line: Brazil’s crunch for COVID-19 intensive care beds

By Stephen Eisenhammer

PIRATININGA, Brazil (Reuters) – José Roberto Inácio spent much of his life ferrying the sick and injured to the hospital in this quiet Brazilian town.

On Wednesday, March 10, the retired ambulance driver took the familiar route once more – as a passenger gasping for breath.

By the weekend, the 63-year-old’s kidneys were failing. He needed dialysis. He needed intensive care.

But at the small hospital where he was being treated even basic medical supplies, like a catheter, were lacking. He joined the list for a bed in an intensive care unit (ICU), but doctors told his family there were 70 people in this part of Sao Paulo state already in line.

Bauru, the nearest major town, only has 50 intensive care beds – and all were full.

Inácio died waiting.

“All his life he worked to save people, but in the hour that he needed help, there was nothing for him,” Inácio’s son Roberto, 41, told Reuters, eyes still blank with shock. “You watch a person dying, and you can’t do anything about it.”

Inácio was one of 3,251 people in Brazil killed by COVID-19 on March 23, then the highest daily death toll since the pandemic began. Around the world, nearly one in three COVID-19 deaths were Brazilian. Inácio was one.

“He’s become a statistic,” his son said.

As much of the world appears to be emerging from the worst of the pandemic, Brazil’s health system is buckling.

Across the country there are over 6,000 people waiting for an ICU bed, according to government data. In 15 of Brazil’s 26 states, ICU capacity is at or above 90% full, as the country’s P1 variant fuels a second wave far deadlier than the first.

Even in Sao Paulo, Brazil’s wealthiest state with a sophisticated public hospital network, scores are dying in line for intensive care.

Despite the crisis, President Jair Bolsonaro continues to ridicule stay-at-home measures. He rarely wears a mask and has said he does not plan to get vaccinated. He told Brazilians to “stop whining” about the number of dead, now over 300,000 – the world’s second-highest toll behind the United States.

Brazil, a major global economy once lauded for its public health victories, has also been slow to secure vaccines for its 210 million inhabitants. Less than 10% of adults have received a first dose and only 3% are fully vaccinated.

Epidemiologists fear the worst is yet to come.

“This is going to be devastating,” said Albert Ko, a professor at Yale School of Public Health with decades of experience in Brazil. “Unless there’s a change in federal and state government policies, towards implementing effective lockdowns, we’re looking at a real humanitarian crisis.”

SILENT BURIAL

A giant billboard of Bolsonaro greets visitors to Bauru, a town of 400,000 about a four-hour drive from Sao Paulo.

The mayor, Suéllen Rosim, has railed against lockdown measures and aligned herself with the far-right leader. Last month, she defied a state government order to close nonessential businesses, allowing many to remain open despite surging COVID-19 cases.

A court ruling finally forced her to comply, but she continues to argue lockdowns are ineffective despite overwhelming evidence they have worked across the globe.

“There’s no science that shows that if I lock everyone up at home, everything will get better,” she told Reuters. “Bars and restaurants have been shut for weeks and the numbers haven’t stopped going up.”

She blamed the state for a lack of ICU capacity.

In response, the Sao Paulo government said it was working to increase the number of hospital beds in Bauru and across the region. The state criticized the municipality, which it said did not fund a single intensive care bed.

“The town is also responsible for the increase of intensive care and should do its part,” the state said in a note to Reuters.

On Bauru’s front line, doctors are exhausted; understaffed and under-resourced against the relentless tide of infections.

“People have been talking for months about the risk of the public health system collapsing,” said Fred Nicácio, a doctor treating COVID-19 patients in Bauru. “Sadly, that moment has come.”

Ambulances dart across town carrying patients connected to green oxygen canisters, their belongings in black trash bags by their feet.

One patient in his 40’s, between concentrated breaths, said he now understood the virus was no joke, as medics wheeled him into the hospital.

Beds are so scarce in Bauru that desperate relatives are turning to the courts, hiring lawyers to secure injunctions that would force hospitals – public or private – to take in patients.

But lawyers cannot create ICU beds where there are none. Even private hospitals are struggling, sometimes begging the public sector to take patients needing intensive care off their waitlists.

Inácio’s son is haunted by the belief that his father’s death could have been avoided. If a vaccine had reached him in time, if his hospital had an extra catheter, if an ICU bed had become available.

Last Wednesday, one week after entering the hospital he knew so well, Inácio was buried.

Four men in white hazmat suits drove his body in a minivan the two blocks to the cemetery. They carted the wooden coffin between the rows of dead to a break in the red dirt.

No words were spoken. The only sound was the scratching of mortar and brick as the tomb was sealed.

From a distance, his son watched.

(Reporting by Stephen Eisenhammer; Additional reporting by Leonardo Benassatto; Editing by Brad Haynes and Jonathan Oatis)

WHO says COVID-19 probably passed from bats to humans through another animal: AP

(Reuters) – A joint WHO-China study on the origins of COVID-19 says that the virus was probably transmitted from bats to humans through another animal, and that a lab leak was “extremely unlikely” as a cause, the Associated Press reported on Monday.

The reported findings match what WHO officials have said in the past about their conclusions following a Jan-Feb visit to China.

Many questions remain unanswered, and the team proposed further research in every area except the lab leak hypothesis, the Associated Press reported, citing a draft copy it had obtained.

WHO director-general Tedros Adhanom Ghebreysus acknowledged receipt of the report from the independent experts but declined to give details, telling a Geneva news briefing: “All hypotheses are on the table and warrant complete and further studies.”

The 400-page report, drawn up by the team which carried out a mission to the central Chinese city of Wuhan where the virus was first encountered in late 2019, is to be issued on Tuesday after diplomats from WHO’s 194 member states are briefed on its findings, Tedros said.

Germany’s international development minister Gerd Mueller, speaking to the same briefing after holding talks with Tedros, welcomed China’s cooperation with the probe.

The United States expects the WHO-led investigation to require further study of the SARS-CoV-2 virus, perhaps including a return visit to China, a senior U.S. official told reporters last week. He hoped it would be “based on science”.

The probe was plagued by delays, concern over access and bickering between Beijing and Washington, which under former U.S. President Donald Trump’s administration accused China of hiding the extent of the initial outbreak.

(Reporting by Nandakumar D in Bengaluru and Stephanie Nebehay and Emma Farge in Geneva; Editing by Himani Sarkar and Peter Graff)